SCHEMBL5113381

SCHEMBL5113381

Cc1ccc(S(=O)(=O)n2ccc3c(NC(C)C)nc(I)nc32)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.45
ACVR1 Q04771 1/20 0.39
RXFP1 Q9HBX9 2/20 0.38
BRD4 O60885 1/20 0.37
POLB P06746 2/20 0.36
HTT P42858 2/20 0.36
ALDH3A1 P30838 1/20 0.36
NOD1 Q9Y239 1/20 0.36
ALDH1A1 P00352 2/20 0.35
GAA P10253 2/20 0.35
RAPGEF4 Q8WZA2 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
PKM P14618 2/20 0.34
HTR6 P50406 3/20 0.34
ATR Q13535 1/20 0.34
ATRIP Q8WXE1 1/20 0.34
KLK7 P49862 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5124281 0.89 L3MBTL1 (0.42) L3MBTL1ACVR1BRD4POLBHTT
SCHEMBL5123488 0.86 L3MBTL1 (0.45) L3MBTL1ACVR1RXFP1BRD4POLB
SCHEMBL5117141 0.85 L3MBTL1 (0.43) L3MBTL1ACVR1BRD4POLBHTT
SCHEMBL5116653 0.84 L3MBTL1 (0.45) L3MBTL1ACVR1BRD4POLBHTT
SCHEMBL5124659 0.84 L3MBTL1 (0.45) L3MBTL1ACVR1BRD4POLBHTT
SCHEMBL14547910 0.81 KCNH3 (0.48) L3MBTL1ACVR1CA1CA2
SCHEMBL5116808 0.80 L3MBTL1 (0.42) L3MBTL1ACVR1BRD4POLBHTT
SCHEMBL4793803 0.79 L3MBTL1 (0.50) L3MBTL1BRD4POLBHTTALDH3A1
SCHEMBL12085380 0.78 HPGD (0.45) L3MBTL1ACVR1POLBALDH1A1GAA
SCHEMBL4723463 0.77 MAPT (0.41) L3MBTL1ACVR1POLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004295-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-01-03 US disclosed
US-20080004295-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-01-03 US disclosed
US-20080004295-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004295-A1 NOVEL COMPOUNDS SYK, BTK, LCK L3MBTL1 3847/4885ACVR1 4241/4885RXFP1 3432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.